Immunomodulatory and Protective Effects of Moxifloxacin againstCandida albicans-Induced Bronchopneumonia in Mice Injected with Cyclophosphamide
Open Access
- 1 August 2002
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (8) , 2442-2449
- https://doi.org/10.1128/aac.46.8.2442-2449.2002
Abstract
In a previous study, moxifloxacin was shown to ameliorate immunosuppression and enhance cytokine production in several tissues, including the lungs of cyclophosphamide-injected mice. We examined here the effects of moxifloxacin onCandida albicanslung infection in cyclophosphamide-injected mice. Mice were injected on day 0 with 250 mg of cyclophosphamide/kg, and on days 1 to 4 they were given moxifloxacin at 22.5 mg/kg/day compared to controls given ceftazidime at 75 mg/kg/day or saline. On day 6,C. albicans(10 7 CFU/mouse) was inoculated intratracheally, and animals were observed for the development of bronchopneumonia, weight loss, mortality, the presence ofC. albicans, and lung cytokine production. Histopathology on day 10 postinoculation revealed bronchopneumonia in 50, 67, and 0% of saline-, ceftazidime-, and moxifloxacin-treated mice, respectively (P < 0.05). The mortality rates were 28, 17, and 5%, respectively (P < 0.05), and weight loss occurred at 20, 32, and 0%, respectively (P < 0.05). By day 15,C. albicanswas eliminated from all moxifloxacin-treated mice but was still isolated from lung homogenates of 50 to 60% of the saline- and ceftazidime-treated groups. Among the cytokines tested on days 0 to 15, we found an increased production of tumor necrosis factor alpha, KC (functional interleukin-8), and gamma interferon in the lungs of ceftazidime- and saline-treated controls compared to the moxifloxacin pretreatment that abolished their secretion. In conclusion, moxifloxacin protected cyclophosphamide-injected mice fromC. albicans-induced lung infection and significantly reduced pneumonia, weight loss, and mortality despite the lack of direct antifungal activity. This is most likely due to an immunomodulating activity conferred by moxifloxacin, as shown in this model and in our previous studies. Its potential protective role should be studied in patients undergoing chemotherapy and immune suppression.Keywords
This publication has 33 references indexed in Scilit:
- Mechanisms of the Proinflammatory Response of Endothelial Cells toCandida albicansInfectionInfection and Immunity, 2000
- A Double-Blind Comparison of Empirical Oral and Intravenous Antibiotic Therapy for Low-Risk Febrile Patients with Neutropenia during Cancer ChemotherapyNew England Journal of Medicine, 1999
- Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin-3 and granulocyte-macrophage colony-stimulating factor expressionArthritis & Rheumatism, 1998
- Responsiveness of human polymorphonuclear cells (PMNL) to stimulation by a mannoprotein fraction (MP-F2) of Candida albicans; enhanced production of IL-6 and tumour necrosis factor-alpha (TNF-α) by MP-F2-stimulated PMNL from HIV-infected subjectsClinical and Experimental Immunology, 1997
- Candida albicans induces the release of inflammatory mediators from human peripheral blood monocytesInflammation, 1996
- Increased interleukin 2 transcription in murine lymphocytes by ciprofloxacinImmunopharmacology, 1994
- Interleukin 8 in serum in granulocytopenic patients with infectionsBritish Journal of Haematology, 1994
- Induction of Tumor Necrosis Factor- in Murine Candida albicans InfectionThe Journal of Infectious Diseases, 1993
- Effects of quinolones on tumor necrosis factor production by human monocytesInternational Journal of Immunopharmacology, 1990
- The effect of ciprofloxacin and pefloxacin on bone marrow engraftment in the spleen of miceJournal of Antimicrobial Chemotherapy, 1989